ArticleThe Journal of investigative dermatology2014

A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.

Maryline Allegra et al.PubMed ↗Publisher ↗

No numbers read from the abstract.